{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:38:47Z","timestamp":1793831927209,"version":"4.6.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"vor","delay-in-days":385,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jacc.2021.07.065","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T15:14:31Z","timestamp":1639408471000},"page":"2505-2517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":170,"title":["Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic\u00a0Cardiomyopathy"],"prefix":"10.1016","volume":"78","author":[{"given":"Anne M.","family":"Dybro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten B.","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni R.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads J.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten K.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen H.","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.jacc.2021.07.065_bib1","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacc.2021.07.065_bib2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJMoa021332","article-title":"Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy","volume":"348","author":"Maron","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"30","key":"10.1016\/j.jacc.2021.07.065_bib3","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/eurheartj\/eht439","article-title":"A\u00a0novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM\u00a0risk-SCD)","volume":"35","author":"O\u2019Mahony","year":"2014","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.jacc.2021.07.065_bib4","first-page":"221","article-title":"Functional obstruction of the left ventricle; acquired aortic subvalvar stenosis","volume":"106","author":"Brock","year":"1957","journal-title":"Guys Hosp Rep"},{"key":"10.1016\/j.jacc.2021.07.065_bib5","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0002-9149(62)90373-9","article-title":"Hemodynamic alterations in idiopathic hypertrophic subaortic stenosis induced by sympathomimetic drugs","volume":"10","author":"Braunwald","year":"1962","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2021.07.065_bib6","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1161\/01.CIR.29.3.422","article-title":"The Circulatory response of patients with idiopathic hypertrophic subaortic stenosis to nitroglycerin and to the Valsalva maneuver","volume":"29","author":"Braunwald","year":"1964","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jacc.2021.07.065_bib7","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJM199703133361107","article-title":"The management of hypertrophic cardiomyopathy","volume":"336","author":"Spirito","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"39","key":"10.1016\/j.jacc.2021.07.065_bib8","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.jacc.2021.07.065_bib9","first-page":"e558","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.jacc.2021.07.065_bib10","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/eurheartj\/ehs150","article-title":"Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence","volume":"33","author":"Spoladore","year":"2012","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.jacc.2021.07.065_bib11","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/01.CIR.35.5.847","article-title":"Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade","volume":"35","author":"Cohen","year":"1967","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jacc.2021.07.065_bib12","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/01.CIR.38.5.846","article-title":"Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol","volume":"38","author":"Flamm","year":"1968","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacc.2021.07.065_bib13","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/hrt.32.6.804","article-title":"Long-term propranolol therapy in muscular subaortic stenosis","volume":"32","author":"Adelman","year":"1970","journal-title":"Br Heart J"},{"issue":"6","key":"10.1016\/j.jacc.2021.07.065_bib14","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/0002-9149(73)90012-X","article-title":"Hypertrophic subaortic stenosis. Clinical and hemodynamic effects of long-term propranolol therapy","volume":"31","author":"Stenson","year":"1973","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.jacc.2021.07.065_bib15","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.006853","article-title":"Study design and rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy","volume":"13","author":"Ho","year":"2020","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.jacc.2021.07.065_bib16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/14656566.2019.1702023","article-title":"Pharmacotherapy for the treatment of obstructive hypertrophic cardiomyopathy","volume":"1","author":"Spoladore","year":"2020","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"10.1016\/j.jacc.2021.07.065_bib17","first-page":"523","article-title":"A\u00a0category-ratio perceived exertion scale: relationship to blood and muscle lactates and heart rate","volume":"15","author":"Noble","year":"1983","journal-title":"Med Sci Sports Exerc"},{"issue":"5","key":"10.1016\/j.jacc.2021.07.065_bib18","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.amjcard.2012.04.051","article-title":"beta Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy","volume":"110","author":"Nistri","year":"2012","journal-title":"Am J Cardiol"},{"issue":"9","key":"10.1016\/j.jacc.2021.07.065_bib19","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jacc.2013.06.007","article-title":"Paradoxical response to exercise in asymptomatic hypertrophic cardiomyopathy: a new description of outflow tract obstruction dynamics","volume":"62","author":"Lafitte","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.07.065_bib20","series-title":"Clinical Trials: A Practical Approach","first-page":"116","article-title":"Crossover trials","author":"Pocock","year":"1983"},{"issue":"11","key":"10.1016\/j.jacc.2021.07.065_bib21","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1136\/hrt.35.11.1116","article-title":"Double-blind trial of propranolol and practolol in hypertrophic cardiomyopathy","volume":"35","author":"Hubner","year":"1973","journal-title":"Br Heart J"},{"issue":"17","key":"10.1016\/j.jacc.2021.07.065_bib22","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/0002-9149(88)90268-8","article-title":"Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration","volume":"62","author":"Pollick","year":"1988","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.jacc.2021.07.065_bib23","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/0735-1097(93)90386-F","article-title":"A\u00a0double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy","volume":"21","author":"Gilligan","year":"1993","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jacc.2021.07.065_bib24","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1159\/000175883","article-title":"Effect of sotalol on arrhythmias and exercise tolerance in patients with hypertrophic cardiomyopathy","volume":"82","author":"Tendera","year":"1993","journal-title":"Cardiology"},{"issue":"6","key":"10.1016\/j.jacc.2021.07.065_bib25","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1161\/01.CIR.60.6.1208","article-title":"Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status","volume":"60","author":"Rosing","year":"1979","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jacc.2021.07.065_bib26","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.chest.2020.05.552","article-title":"Performance and interpretation of invasive hemodynamic exercise testing","volume":"158","author":"Jain","year":"2020","journal-title":"Chest"},{"issue":"14","key":"10.1016\/j.jacc.2021.07.065_bib27","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.jacc.2013.03.055","article-title":"Significance of high-sensitivity cardiac troponin T in hypertrophic cardiomyopathy","volume":"62","author":"Kubo","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.jacc.2021.07.065_bib28","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1016\/j.jacc.2013.04.004","article-title":"B-type natriuretic peptide and survival in hypertrophic cardiomyopathy","volume":"61","author":"Geske","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.jacc.2021.07.065_bib29","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Sherrid","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jacc.2021.07.065_bib30","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1161\/CIRCHEARTFAILURE.112.967026","article-title":"Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging","volume":"5","author":"Olivotto","year":"2012","journal-title":"Circ Heart Fail"},{"issue":"16","key":"10.1016\/j.jacc.2021.07.065_bib31","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1161\/01.CIR.0000162460.36735.71","article-title":"Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy","volume":"111","author":"Woo","year":"2005","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacc.2021.07.065_bib32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jtcvs.2018.08.062","article-title":"Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a propensity score-matched cohort","volume":"157","author":"Nguyen","year":"2019","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"issue":"19","key":"10.1016\/j.jacc.2021.07.065_bib33","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/eurheartj\/ehv693","article-title":"Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry","volume":"37","author":"Veselka","year":"2016","journal-title":"Eur Heart J"},{"issue":"10253","key":"10.1016\/j.jacc.2021.07.065_bib34","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"issue":"10293","key":"10.1016\/j.jacc.2021.07.065_bib35","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Spertus","year":"2021","journal-title":"Lancet"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721078888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721078888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:47:14Z","timestamp":1760017634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109721078888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":35,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0735109721078888"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2021.07.065","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.741312351.793591816","asserted-by":"object"}]},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic\u00a0Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2021.07.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}